Medicus Pharma Ltd. Common Stock (MDCX) 10-Year Financial Performance & Capital Metrics

MDCX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutMedicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.Show more

Revenue $0
EBITDA -$11M -319.6%
Net Income -$11M -109.9%
EPS (Diluted) -1.10 +28.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -525.44% -9.9%
ROIC -
Debt/Equity 0.10
Interest Coverage -35.21 -343.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-158.55%

EPS CAGR

10Y-

5Y-

3Y-

TTM9.84%

ROCE

10Y Avg-463.92%

5Y Avg-463.92%

3Y Avg-463.92%

Latest-502.28%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	1.44M	978.42K	4.73M	11.18M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	258.01K	332.03K	2.46M	7.65M
SG&A % of Revenue	-	-	-	-
Research & Development	1.18M	646.38K	193.58K	3.53M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	2.07M	0
Operating Income+	-1.44M	-978.42K	-4.73M	-11.18M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	0.32%	-3.83%	-1.36%
EBITDA+	-1.94M	-1.17M	-2.66M	-11.16M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	0.4%	-1.28%	-3.2%
D&A (Non-Cash Add-back)	0	0	2.07M	0
EBIT	-1.94M	-1.17M	-2.66M	-11.16M
Net Interest Income+	-690.85K	-1.1M	-584.82K	-213.13K
Interest Income	-575.45K	-575.45K	10.72K	104.41K
Interest Expense	115.41K	526.83K	595.54K	317.54K
Other Income/Expense	-613.88K	-713.97K	-584.82K	25.39K
Pretax Income+	-2.06M	-1.69M	-5.31M	-11.16M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-2.06M	-1.69M	-5.31M	-11.16M
Net Margin %	-	-	-	-
Net Income Growth %	-	0.18%	-2.14%	-1.1%
Net Income (Continuing)	-2.06M	-1.69M	-5.31M	-11.16M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.26	-0.21	-1.53	-1.10
EPS Growth %	-	0.19%	-6.29%	0.28%
EPS (Basic)	-0.26	-0.88	-1.53	-1.10
Diluted Shares Outstanding	8.05M	8.05M	3.48M	9.62M
Basic Shares Outstanding	8.05M	1.93M	3.48M	9.62M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	78.51K	282.65K	1.89M	5.38M
Cash & Short-Term Investments	78.51K	267.65K	1.72M	4.16M
Cash Only	78.51K	267.65K	1.72M	4.16M
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	0	0	0	0
Total Non-Current Assets+	0	0	0	268.57K
Property, Plant & Equipment	0	0	0	268.57K
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	0	0	0
Total Assets+	78.51K	282.65K	1.89M	5.65M
Asset Turnover	-	-	-	-
Asset Growth %	-	2.6%	5.7%	1.98%
Total Current Liabilities+	10.58M	12.48M	781.61K	2.31M
Accounts Payable	0	0	210.84K	1.28M
Days Payables Outstanding	-	-	-	-
Short-Term Debt	667.93K	1.53M	0	116.32K
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	9.92M	10.95M	27.77K	140.99K
Current Ratio	0.01x	0.02x	2.42x	2.33x
Quick Ratio	0.01x	0.02x	2.42x	2.33x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	0	0	0	205.94K
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	0	205.82K
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	0
Total Liabilities	10.58M	12.48M	781.61K	2.51M
Total Debt+	667.93K	1.53M	0	322.27K
Net Debt	589.42K	1.26M	-1.72M	-3.84M
Debt / Equity	-	-	-	0.10x
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-12.49x	-1.86x	-7.94x	-35.21x
Total Equity+	-10.51M	-12.2M	1.11M	3.13M
Equity Growth %	-	-0.16%	1.09%	1.82%
Book Value per Share	-1.31	-1.52	0.32	0.33
Total Shareholders' Equity	-10.51M	-12.2M	1.11M	3.13M
Common Stock	194.54K	194.54K	18.76M	30.52M
Retained Earnings	-10.7M	-12.39M	-17.75M	-28.9M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.45M	-1.06M	-4.16M	-10.25M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	0.27%	-2.93%	-1.46%
Net Income	-2.06M	-1.69M	-5.31M	-11.16M
Depreciation & Amortization	0	0	0	0
Stock-Based Compensation	0	0	98.58K	713.12K
Deferred Taxes	0	0	0	0
Other Non-Cash Items	613.88K	713.97K	584.82K	162.24K
Working Capital Changes	-6.66K	-78.69K	473.1K	32.93K
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	0	0	79.09K	808.75K
Cash from Investing+	0	0	0	0
Capital Expenditures	0	0	0	0
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	882.38K	1.25M	5.61M	12.69M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	0	5.11M	0
Net Change in Cash	-	-	-	-
Free Cash Flow+	-1.45M	-1.06M	-4.16M	-10.25M
FCF Margin %	-	-	-	-
FCF Growth %	-	0.27%	-2.93%	-1.46%
FCF per Share	-0.18	-0.13	-1.20	-1.07
FCF Conversion (FCF/Net Income)	0.70x	0.62x	0.78x	0.92x
Interest Paid	0	0	0	40.56K
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-478.18%	-525.44%
Debt / Equity	-	-	-	0.10x
Interest Coverage	-12.49x	-1.86x	-7.94x	-35.21x
FCF Conversion	0.70x	0.62x	0.78x	0.92x

Frequently Asked Questions

Growth & Financials

Medicus Pharma Ltd. Common Stock (MDCX) grew revenue by 0.0% over the past year. Growth has been modest.

Medicus Pharma Ltd. Common Stock (MDCX) reported a net loss of $29.5M for fiscal year 2024.

Dividend & Returns

Medicus Pharma Ltd. Common Stock (MDCX) has a return on equity (ROE) of -525.4%. Negative ROE indicates the company is unprofitable.

Medicus Pharma Ltd. Common Stock (MDCX) had negative free cash flow of $19.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener